
Advanced Reproductive Testing LLC (AKA: ART~cradle Genomics Inc) Profile last edited on: 7/20/2023
CAGE: 67JU0
UEI: WZNAC5PU62K3
Business Identifier: Innovative fetal care: fetus DNA Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 11
County: Oakland
Congr. District: 11
County: Oakland
Public Profile
Advanced Reproductive Testing (ART) is developing technologies designed to advance the detection and treatment of pregnancy related disorders, providing clinicians and expecting parents the information needed to manage pregnancies at risk. The team is currently developing a new product line named papseek - safe and simple tests that will be able to educate families and clinicians about the status of pregnancy and the genetic health of the baby as early as five weeks of pregnancy. The effort is to make available a 'standard' sampling kit that can be used safely by a health professional to collect and ship a sample. Samples will be de-identified to protect customer privacy and made accessible according to federal laws and regulations. The first set of tests under development are focused on gender determination and on the genetic carrier status (Sickle cell) from DNA of the baby obtained by the pap smear.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
10-14Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2020 | 2 | NIH | $2,299,998 | |
Project Title: A Platform for Safe, Noninvasive Prenatal Genetic Testing at Five Weeks of Pregnancy | ||||
2018 | 1 | NIH | $299,992 | |
Project Title: A Noninvasive Platform to Assess Maternal Risk for Perinatal Complications in the First Trimester | ||||
2018 | 1 | NIH | $299,969 | |
Project Title: A Noninvasive Prenatal Testing Platform for Aneuploidy At Five Weeks of Gestation |
Key People / Management
David R Armant
Sascha Drewlo -- Chief Operating Executive
Leena Kadam
Hamid-Reza Kohan-Ghadr
Sascha Drewlo -- Chief Operating Executive
Leena Kadam
Hamid-Reza Kohan-Ghadr